Call 800 665 0411 to learn about our services for your stock

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS

Share on StockTwits

Massachusetts Biotech Advances Novel Cytokine Therapies

Source: Dr. Robert Driscoll


November 16, 2023 ( Newswire) Wedbush sees over 300% upside for Werewolf stock based on early clinical success for its PREDATOR platform and pipeline, according to a WedBush research note.

Cambridge, Massachusetts-based Werewolf Therapeutics Inc. (HOWL:NASDAQ) reported Q3 2023 results and progress for its pipeline of INDUKINE product candidates, noted Wedbush analyst Dr. Robert Driscoll in a November 15 research report.

The analysts have an Outperform rating and US$9 price target on Werewolf Therapeutics.

Early Efficacy Signals Seen for Lead Candidate

According to the analysts, Werewolf's WTX-124 INDUKINE therapy has shown initial proof-of-concept with a differentiated safety profile compared to standard high-dose IL-2 and evidence of antitumor activity in early studies.

At the 12 mg dose, WTX-124 yielded a partial response in a melanoma patient and disease control in lung cancer patients. The company is now testing an 18 mg dose cohort.

The analysts believe this data validates Werewolf's novel INDUKINE approach to conditionally activating cytokines within tumors while limiting systemic toxicity.

Advancing Broad Pipeline

Beyond WTX-124, Werewolf is evaluating the second INDUKINE candidate, WTX-330, in dose escalation and plans to share preclinical data on WTX-518 in 2024.

The company is also progressing IL-21 INDUKINE WTX-712 towards the clinic based on encouraging preclinical results.

Significant Upside from Current Levels

Wedbush maintains an Outperform rating on Werewolf Therapeutics and a US$9 price target, seeing over 300% upside for the shares.

The firm's valuation is based on projected 2031 sales for WTX-124 applied to standard revenue multiples.

In summary, the analysts see Werewolf's INDUKINE platform and early WTX-124 efficacy as validating the company's novel approach to cytokine therapies in oncology. With multiple clinical catalysts upcoming, they view the risk/reward as favorable.

More Info: Newswire

This news is published on the Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire

Global investors must adhere to regulations of each country. Please read privacy policy:

That's all it takes to get an article published on Investor Ideas - Learn More - A Leading Global Investor Website for Biotech Industry Stocks - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Buy a biotech guest post on